Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
TSVT 2seventy bio
14.130+0.140+1.00%
Close
02/03 16:00 ET
14.470+0.340+2.41%
Post Mkt Price 02/03 19:57 ET
High
14.520
Open
13.660
Turnover
10.23M
Low
13.660
Pre Close
13.990
Volume
723.15K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Wedbush Raises 2seventy Bio's Price Target to $30 From $28, Keeps Outperform Rating
07:18 AM EST, 02/03/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Analysts Offer Insights on Healthcare Companies: Dyadic International (DYAI), Biophytis (BPTS) and 2seventy Bio (TSVT)
2seventy Bio Says ABECMA Generated ~$94M In U.S. Revenue In Q4 2022; ~$297M In U.S. Revenue For FY22
https://www.sec.gov/ix?doc=/Archives/edgar/data/1860782/000186078223000012/tvst-20230202.htm
2seventy Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will participate in the following upcoming investor conferences: Guggenheim On
How Much Upside Is Left in 2seventy Bio, Inc. (TSVT)? Wall Street Analysts Think 127.63%
Investors in 2seventy Bio (NASDAQ:TSVT) From a Year Ago Are Still Down 32%, Even After 25% Gain This Past Week
2seventy bio, Inc. (NASDAQ:TSVT) shareholders will doubtless be very grateful to see the share price up 35% in the last month. But that is minimal compensation for the share price under-performance
Morgan Stanley Remains a Buy on 2seventy Bio (TSVT)
Morgan Stanley Trims Price Target on 2seventy Bio to $28 From $29, Maintains Overweight Rating
09:16 AM EST, 01/24/2023 (MT Newswires) -- 2seventy bio (TSVT) has an average rating of buy and price targets ranging from $27 to $34, according to analysts polled by Capital IQ.
2seventy Bio Price Target Cut to $28.00/Share From $29.00 by Morgan Stanley
2seventy Bio Price Target Cut to $28.00/Share From $29.00 by Morgan Stanley
2seventy Bio Is Maintained at Overweight by Morgan Stanley
2seventy Bio Is Maintained at Overweight by Morgan Stanley
Company Overview
More
2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.
CEO： Mr. Nick Leschly
Market： NASDAQ
Listing Date： 10/18/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet